PRB2 and neoplasm: This finding suggests that ANV, as a PS recognition protein, may be used to deliver specific cytotoxic drugs that selectively destroy blood vessels in solid tumors, thus indicating that it is a novel inhibitor of angiogenesis in tumor therapy.